MENU
+Compare
XBI
ETF ticker: NYSE ARCA
AS OF
Sep 5 closing price
Price
$95.47
Change
+$2.00 (+2.14%)
Net Assets
5.39B

XBI stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U... Show more

Category: #Health
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for XBI with price predictions
Sep 04, 2025

Momentum Indicator for XBI turns positive, indicating new upward trend

XBI saw its Momentum Indicator move above the 0 level on September 02, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for XBI just turned positive on August 13, 2025. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

The 50-day moving average for XBI moved above the 200-day moving average on September 02, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XBI broke above its upper Bollinger Band on September 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Exact Sciences Corp (NASDAQ:EXAS), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Biotech ETF ETF is 8.75B. The market cap for tickers in the group ranges from 158.59M to 375.5B. ABBV holds the highest valuation in this group at 375.5B. The lowest valued company is SCLX at 158.59M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Biotech ETF ETF was 6%. For the same ETF, the average monthly price growth was 11%, and the average quarterly price growth was 9%. OLMA experienced the highest price growth at 52%, while SPRY experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Biotech ETF ETF was 19%. For the same stocks of the ETF, the average monthly volume growth was -17% and the average quarterly volume growth was 12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 79
Price Growth Rating: 53
SMR Rating: 88
Profit Risk Rating: 85
Seasonality Score: -29 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com